Insaf-Meriem Boutemine1, Manel Amri2, Zine-Charaf Amir3, Catherine Fitting4, Samira Mecherara-Idjeri5, Karim Layaida6, Nacira Sennoun7, Saadi Berkane8, Jean-Marc Cavaillon9, Chafia Touil-Boukoffa10. 1. Team "Cytokines and NO Synthases", LBCM (Laboratory of Cellular and Molecular Biology), FSB (Faculty of Biological Science), USTHB (University of Sciences and Technology Houari Boumediene), PB 32 El-Alia, 16111 Algiers, Algeria. Electronic address: insaf91@live.fr. 2. Team "Cytokines and NO Synthases", LBCM (Laboratory of Cellular and Molecular Biology), FSB (Faculty of Biological Science), USTHB (University of Sciences and Technology Houari Boumediene), PB 32 El-Alia, 16111 Algiers, Algeria. Electronic address: manelamri@yahoo.fr. 3. Pathology department, Mustapha Pacha Hospital, Algiers, Algeria. Electronic address: z_c_amir@yahoo.fr. 4. Cytokines & Inflammation, Pasteur Institute, Paris, France. Electronic address: catherine.fitting@pasteur.fr. 5. LAOF (Laboratory of Systematic Functional Organic Analysis), Faculty of Chemistry, USTHB (University of Sciences and Technology Houari Boumediene), Algiers, Algeria. Electronic address: mecherarasamira@yahoo.fr. 6. Gastroenterology department, Mustapha Pacha Hospital, Algiers, Algeria. Electronic address: layaidak@yahoo.fr. 7. Team "Cytokines and NO Synthases", LBCM (Laboratory of Cellular and Molecular Biology), FSB (Faculty of Biological Science), USTHB (University of Sciences and Technology Houari Boumediene), PB 32 El-Alia, 16111 Algiers, Algeria. Electronic address: nsennoun@hotmail.fr. 8. Gastroenterology department, Mustapha Pacha Hospital, Algiers, Algeria. Electronic address: sberkane@yahoo.fr. 9. Cytokines & Inflammation, Pasteur Institute, Paris, France. Electronic address: jean-marc.cavaillon@pasteur.fr. 10. Team "Cytokines and NO Synthases", LBCM (Laboratory of Cellular and Molecular Biology), FSB (Faculty of Biological Science), USTHB (University of Sciences and Technology Houari Boumediene), PB 32 El-Alia, 16111 Algiers, Algeria. Electronic address: touilboukoffa@yahoo.fr.
Abstract
ETHNOPHARMACOLOGICAL RELEVANCE: Pistacia lentiscus L. (Anacardiaceae) (PL) is a flowering plant that grows in the Mediterranean area. It is traditionally used in the treatment of various skin, respiratory and gastrointestinal disorders AIM OF THE STUDY: In the present study, we investigated the anti-ulcerogenic activity of Pistacia lentiscus fatty oil (PLFO) on ethanol-induced gastric ulcers in Wistar rats MATERIAL AND METHODS: PLFO was orally administered to two experimental groups of rats before or after ethanol induction of gastric ulcer. The lesions of the gastric mucosa were evaluated by macroscopic and histopathological examination. In addition, the amount of nitric oxide (NO) and pro-inflammatory cytokines [tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6)] in the supernatant from cultures of gastric mucosa explants were assessed. Finally, the mucus production and iNOS (inducible NO synthase) expression were determined by histochemical and immunohistochemical analysis, respectively RESULT: Our results indicated that the PLFO pretreatment or PLFO treatment significantly reduced ulcerated and hemorrhagic areas. Additionally, pretreatment or treatment with PLFO after ethanol-induced ulceration significantly reduced the plasma concentration of NO. Furthermore, a significant decrease of NO, IL-6 and TNF-α levels was observed in explant culture supernatants. iNOS expression was also reduced in the gastric mucosa. In contrast, mucus production by goblet cells was enhanced. Interestingly, histological analysis of the gastric mucosa has indicated that PLFO- pretreated and treated groups displayed normal histology CONCLUSION: Our results demonstrate that PLFO display significant prophylactic and therapeutic effects against gastric ulcers. Importantly, the mechanism underlying PLFO activities might implicate inhibition of inflammatory responses during gastric ulcer.
ETHNOPHARMACOLOGICAL RELEVANCE: Pistacia lentiscus L. (Anacardiaceae) (PL) is a flowering plant that grows in the Mediterranean area. It is traditionally used in the treatment of various skin, respiratory and gastrointestinal disorders AIM OF THE STUDY: In the present study, we investigated the anti-ulcerogenic activity of Pistacia lentiscus fatty oil (PLFO) on ethanol-induced gastric ulcers in Wistar rats MATERIAL AND METHODS:PLFO was orally administered to two experimental groups of rats before or after ethanol induction of gastric ulcer. The lesions of the gastric mucosa were evaluated by macroscopic and histopathological examination. In addition, the amount of nitric oxide (NO) and pro-inflammatory cytokines [tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6)] in the supernatant from cultures of gastric mucosa explants were assessed. Finally, the mucus production and iNOS (inducible NO synthase) expression were determined by histochemical and immunohistochemical analysis, respectively RESULT: Our results indicated that the PLFO pretreatment or PLFO treatment significantly reduced ulcerated and hemorrhagic areas. Additionally, pretreatment or treatment with PLFO after ethanol-induced ulceration significantly reduced the plasma concentration of NO. Furthermore, a significant decrease of NO, IL-6 and TNF-α levels was observed in explant culture supernatants. iNOS expression was also reduced in the gastric mucosa. In contrast, mucus production by goblet cells was enhanced. Interestingly, histological analysis of the gastric mucosa has indicated that PLFO- pretreated and treated groups displayed normal histology CONCLUSION: Our results demonstrate that PLFO display significant prophylactic and therapeutic effects against gastric ulcers. Importantly, the mechanism underlying PLFO activities might implicate inhibition of inflammatory responses during gastric ulcer.
Authors: Cristian A D Vecchia; Gelvani Locateli; Patricia Z Serpa; Denise Bianchin Gomes; Jackeline Ernetti; Daniela Miorando; Maria Eduarda D C Zanatta; Ruan Kaio Silva Nunes; Silvana M Wildner; Max V Gutiérrez; Wagner Vilegas; Lincon B Somensi; Luisa M Silva; Walter A Roman Junior Journal: Evid Based Complement Alternat Med Date: 2022-08-23 Impact factor: 2.650